BTTX Stock Overview
A prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Better Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.24 |
| 52 Week Low | US$0.000001 |
| Beta | 1.84 |
| 1 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | -99.95% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Better Therapeutics files for FDA approval of new type of digital therapy for diabetes
Sep 22Better Therapeutics GAAP EPS of -$0.42 in-line
Aug 11Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel
May 12Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases
Nov 30Shareholder Returns
| BTTX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 3.2% |
| 1Y | -100.0% | -3.1% | 24.2% |
Return vs Industry: BTTX underperformed the US Healthcare Services industry which returned -3.1% over the past year.
Return vs Market: BTTX underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| BTTX volatility | |
|---|---|
| BTTX Average Weekly Movement | 7,053.3% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BTTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BTTX's weekly volatility has increased from 4139% to 7053% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Frank Karbe | www.bettertx.com |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.
Better Therapeutics, Inc. Fundamentals Summary
| BTTX fundamental statistics | |
|---|---|
| Market cap | US$5.45k |
| Earnings (TTM) | -US$31.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs BTTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$31.57m |
| Earnings | -US$31.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -144.0% |
How did BTTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 11:04 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Better Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Thomas Flaten | Lake Street Capital Markets, LLC |
| Rahul Rakhit | LifeSci Capital, LLC |